Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

Management of age-related osteoporosis and prevention of associated fractures

Authors Eric J MacLaughlin, Rebecca B Sleeper, Danny McNatty, Cynthia L Raehl

Published 15 September 2006 Volume 2006:2(3) Pages 281—295

Eric J MacLaughlin1, Rebecca B Sleeper2, Danny McNatty2, Cynthia L Raehl1

1Department of Pharmacy Practice, Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy, Amarillo, TX, USA; 2Department of Pharmacy Practice, Texas Tech University Health Sciences Center (TTUHSC) School of Pharmacy, Lubbock, TX, USA

Abstract: Osteoporosis and related fractures are a significant concern for the global community. As the population continues to age, morbidity and mortality from fractures due to low bone mineral density (BMD) will likely continue to increase. Efforts should be made to screen those at risk for osteoporosis, identify and address various risk factors for falls and associated fractures, ensure adequate calcium and vitamin D intake, and institute pharmacological therapy to increase BMD when indicated. Agents which increase BMD and have been shown to decrease fractures, particularly at the hip, should be considered preferentially over those for which only BMD data are available. Drugs which have been shown to decrease the risk of age-related osteoporotic fractures include oral bisphosphonates (alendronate, ibandronate, and risedronate), intranasal calcitonin, estrogen receptor stimulators (eg, estrogen, selective estrogen receptor modulators [raloxifene]), parathyroid hormone (teriparatide), sodium fluoride, and strontium ranelate. Data are beginning to emerge supporting various combination therapies (eg, bisphosphonate plus an estrogen receptor stimulator), though more data are needed to identify combinations which are most effective and confer added fracture protection. In addition, further research is needed to identify ideal regimens in special populations such as nursing home patients and men.


Keywords: osteoporosis, fracture, prevention, treatment

Download Article [PDF] 

Readers of this article also read:

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Perindopril for improving cardiovascular events

DiNicolantonio JJ, O’Keefe JH

Vascular Health and Risk Management 2014, 10:539-548

Published Date: 30 August 2014

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Michael J Prematta, Tracy Prematta, Timothy J Craig

Therapeutics and Clinical Risk Management 2008, 4:975-982

Published Date: 10 October 2008

Update on local anesthetics: focus on levobupivacaine

Crina L Burlacu, Donal J Buggy

Therapeutics and Clinical Risk Management 2008, 4:381-392

Published Date: 11 April 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008

Prevention of shingles: safety and efficacy of live zoster vaccine

Dianna Quan, Randall J Cohrs, Ravi Mahalingam, Donald H Gilden

Therapeutics and Clinical Risk Management 2007, 3:633-639

Published Date: 15 September 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007